Henry Piel Email

Executive Director, Quality . Aerovate Therapeutics

Current Roles

Employees:
50
Revenue:
$5.6M
About
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).
Aerovate Therapeutics Address
Boston, MA 02116, US
Boston, MA
United States
Aerovate Therapeutics Email

Past Companies

Aerovate Therapeutics, Inc.Executive Director, Quality
Leap TherapeuticsHead of Quality; Senior Director, Quality Assurance
AMAG PharmaceuticalsHead of Quality; Executive Director, Quality

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.